About aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:LIFE
- CUSIP: 53217V10
- Web: www.atyrpharma.com
Capitalization:- Market Cap: $84.51 million
- Outstanding Shares: 23,806,000
Average Prices:- 50 Day Moving Avg: $3.22
- 200 Day Moving Avg: $3.15
- 52 Week Range: $2.10 - $4.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.54
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $2.13 per share
- Price / Book: 1.67
Profitability:- EBIDTA: ($54,140,000.00)
- Return on Equity: -65.72%
- Return on Assets: -57.31%
Debt:- Current Ratio: 6.17%
- Quick Ratio: 6.17%
Misc:- Average Volume: 123,981 shs.
- Beta: 3.52
- Short Ratio: 1.93
Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) released its quarterly earnings results on Thursday, May, 11th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. View aTyr Pharma's Earnings History.
Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?
3 brokers have issued 1 year target prices for aTyr Pharma's shares. Their predictions range from $2.85 to $4.00. On average, they anticipate aTyr Pharma's share price to reach $3.62 in the next twelve months. View Analyst Ratings for aTyr Pharma.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include VBI Vaccines, Inc. - (VBIV), Genocea Biosciences (GNCA), Peregrine Pharmaceuticals (PPHM), Foamix Pharmaceuticals Ltd (FOMX), Athersys (ATHX), Recro Pharma (REPH), Strongbridge Biopharma plc (SBBP), Vascular Biogenics Ltd (VBLT), Fate Therapeutics (FATE), Mediwound Ltd (MDWD), Uniqure NV (QURE), Conatus Pharmaceuticals (CNAT), MannKind (MNKD), Oncomed Pharmaceuticals (OMED), Pluristem Therapeutics (PSTI), Evogene Ltd (EVGN), BioDelivery Sciences International (BDSI) and Sorrento Therapeutics (SRNE).
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Who owns aTyr Pharma stock?
aTyr Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), EcoR1 Capital LLC (9.65%), Polaris Venture Management Co. V L.L.C. (7.70%), Vanguard Group Inc. (1.83%), Geode Capital Management LLC (0.47%) and Dimensional Fund Advisors LP (0.24%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Who sold aTyr Pharma stock? Who is selling aTyr Pharma stock?
Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?
aTyr Pharma's stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Renaissance Technologies LLC and Geode Capital Management LLC. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.
How do I buy aTyr Pharma stock?
Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of aTyr Pharma stock cost?
One share of aTyr Pharma stock can currently be purchased for approximately $3.55.
Earnings History for aTyr Pharma (NASDAQ:LIFE)Earnings History by Quarter for aTyr Pharma (NASDAQ:LIFE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/11/2017 | Q1 2017 | ($0.50) | ($0.56) | | | View | N/A |  |
| 11/14/2016 | Q3 2016 | ($0.67) | ($0.58) | | | View | N/A | |
| 8/10/2016 | Q216 | ($0.71) | ($0.65) | | | View | N/A | |
| 5/11/2016 | Q1 | ($0.70) | ($0.68) | | | View | N/A | |
| 3/30/2016 | Q4 | ($0.52) | ($0.70) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.48) | ($0.48) | | | View | N/A | |
| 8/12/2015 | Q215 | ($0.53) | ($0.74) | | | View | N/A | |
| 6/18/2015 | Q115 | ($0.41) | ($0.38) | | | View | N/A | |
| 11/5/2013 | Q313 | $0.97 | $1.02 | $926.10 million | $936.00 million | View | N/A | |
| 7/31/2013 | Q2 2013 | $0.96 | $0.72 | $952.06 million | $944.00 million | View | N/A | |
| 5/2/2013 | Q1 2013 | $1.04 | $1.07 | $958.56 million | $963.00 million | View | N/A | |
| 2/4/2013 | Q4 2012 | $1.11 | $1.11 | $988.85 million | $998.90 million | View | N/A | |
| 11/1/2012 | Q312 | $0.89 | $0.92 | $907.91 million | $911.00 million | View | N/A | |
| 7/31/2012 | | $0.97 | $0.96 | | | View | N/A | |
| 2/7/2012 | | $1.04 | $1.06 | | | View | N/A | |
| 10/25/2011 | | $0.88 | $0.94 | | | View | N/A | |
| 7/28/2011 | | $0.95 | $0.89 | | | View | N/A | |
| 4/26/2011 | | $0.85 | $0.85 | | | View | N/A | |
| 2/3/2011 | | $0.87 | $0.90 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)2017 EPS Consensus Estimate: ($2.17)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.49) | ($0.49) | ($0.49) |
| Q2 2017 | 1 | ($0.50) | ($0.50) | ($0.50) |
| Q3 2017 | 1 | ($0.55) | ($0.55) | ($0.55) |
| Q4 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
(Data provided by Zacks Investment Research)
Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)Insider Ownership Percentage: 28.90%
Institutional Ownership Percentage: 44.84%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/24/2017 | John Mendlein | CEO | Buy | 124 | $3.00 | $372.00 | |
| 4/20/2017 | John Mendlein | CEO | Buy | 2,552 | $3.00 | $7,656.00 | |
| 12/21/2016 | Paul Schimmel | Director | Buy | 25,000 | $2.28 | $57,000.00 | |
| 12/20/2016 | Ashraf Amanullah | VP | Buy | 11,000 | $2.25 | $24,750.00 | |
| 12/19/2016 | John Mendlein | CEO | Buy | 69,000 | $2.20 | $151,800.00 | |
| 12/16/2016 | Paul Schimmel | Director | Buy | 50,000 | $2.48 | $124,000.00 | |
| 5/11/2016 | Grove Matsuoka | Insider | Buy | 12,412 | $3.04 | $37,732.48 | |
| 4/14/2016 | Paul Schimmel | Director | Buy | 66,219 | $4.18 | $276,795.42 | |
| 4/13/2016 | Paul Schimmel | Director | Buy | 9,835 | $3.85 | $37,864.75 | |
| 4/12/2016 | Paul Schimmel | Director | Buy | 9,127 | $3.71 | $33,861.17 | |
| 4/11/2016 | Paul Schimmel | Director | Buy | 32,659 | $3.57 | $116,592.63 | |
| 4/8/2016 | Paul Schimmel | Director | Buy | 85,000 | $3.22 | $273,700.00 | |
| 4/7/2016 | Paul Schimmel | Director | Buy | 40,000 | $3.19 | $127,600.00 | |
| 4/6/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.20 | $80,000.00 | |
| 4/5/2016 | John Mendlein | CEO | Buy | 2,500 | $3.55 | $8,875.00 | |
| 4/5/2016 | Paul Schimmel | Director | Buy | 25,000 | $3.52 | $88,000.00 | |
| 5/12/2015 | James E Flynn | Insider | Buy | 50,000 | $14.00 | $700,000.00 | |
| 5/12/2015 | Sofinnova Venture Partners Ix, | Major Shareholder | Buy | 320,000 | $14.00 | $4,480,000.00 | |
| 5/29/2013 | David C Uprichard | Director | Sell | 2,010 | $74.04 | $148,820.40 | |
| 5/28/2013 | John A Cottingham | Insider | Sell | 60,000 | $74.03 | $4,441,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
| Source: |
|
| Date | Headline |
|---|
 | aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the American Thoracic Society 2017 International Conference and Will Host an Educational Webinar
finance.yahoo.com - May 15 at 10:38 AM |
 | aTyr Pharma Inc (LIFE) Posts Earnings Results, Misses Expectations By $0.06 EPS
www.americanbankingnews.com - May 12 at 11:48 AM |
 | UPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM |
 | Contract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM |
| aTyr Pharma Announces First Quarter 2017 Operating Results
finance.yahoo.com - May 11 at 6:46 PM |
| Atyr Pharma reports 1Q loss
finance.yahoo.com - May 11 at 6:46 PM |
| -$0.55 Earnings Per Share Expected for aTyr Pharma Inc (LIFE) This Quarter
www.americanbankingnews.com - May 10 at 12:10 AM |
| aTyr Pharma Inc (LIFE) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:18 AM |
| aTyr Pharma (LIFE) Earns Daily News Impact Rating of -0.10
www.americanbankingnews.com - April 28 at 2:44 PM |
 | aTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM |
| aTyr Pharma (LIFE) Earns News Impact Score of -0.12
www.americanbankingnews.com - April 23 at 3:13 PM |
| aTyr Pharma (LIFE) Given Coverage Optimism Rating of -0.06
www.americanbankingnews.com - April 20 at 3:47 PM |
| Zacks: Analysts Expect aTyr Pharma Inc (LIFE) to Post -$0.55 Earnings Per Share
www.americanbankingnews.com - April 19 at 7:56 AM |
| aTyr Pharma (LIFE) Getting Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 14 at 1:08 PM |
| aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors
finance.yahoo.com - April 10 at 5:55 PM |
| Short Interest in aTyr Pharma Inc (LIFE) Drops By 9.3%
www.americanbankingnews.com - April 10 at 3:46 PM |
| aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors - Yahoo Finance
finance.yahoo.com - April 4 at 8:02 AM |
| ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM |
| aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference
finance.yahoo.com - March 29 at 10:10 AM |
| aTyr Pharma Inc (LIFE) Price Target Raised to $4.00 at Citigroup Inc
www.americanbankingnews.com - March 24 at 11:31 AM |
| ATYR PHARMA INC Financials
finance.yahoo.com - March 22 at 6:26 PM |
| aTyr Pharma Inc (LIFE) Given New $4.00 Price Target at Citigroup Inc
www.americanbankingnews.com - March 20 at 12:32 PM |
| aTyr Pharma Inc (LIFE) Given a $4.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 19 at 9:13 PM |
 | aTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results
www.bizjournals.com - March 16 at 7:04 PM |
| ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:04 PM |
| aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived From 20 out of 20 Human tRNA Synthetases
finance.yahoo.com - March 15 at 6:31 PM |
 | aTyr Pharma (LIFE) Gains on Orphan Drug Designation
www.baystreet.ca - March 3 at 11:14 PM |
 | aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
us.rd.yahoo.com - March 3 at 6:13 PM |
| 8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients
us.rd.yahoo.com - March 3 at 6:13 PM |
 | BUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - Nasdaq
www.nasdaq.com - March 2 at 10:18 AM |
| aTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.com
www.streetinsider.com - March 2 at 10:18 AM |
 | aTyr Pharma Rises 16% on Orphan Drug Status (LIFE)
www.investopedia.com - March 1 at 5:58 PM |
| aTyr Pharma Rises 16% on Orphan Drug Status
www.investopedia.com - March 1 at 5:58 PM |
| aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 11:17 AM |
| aTyr Pharma (LIFE) Spikes on FDA Nod
www.baystreet.ca - February 28 at 6:24 PM |
| aTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris
www.streetinsider.com - February 28 at 6:24 PM |
| 8:01 am aTyr Pharma confirms that its product candidate Resolaris was granted Orphan Drug Designation by the FDA for the treatment of limb girdle muscular dystrophy patients
finance.yahoo.com - February 28 at 6:24 PM |
| aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
finance.yahoo.com - February 28 at 9:46 AM |
| High court ruling limits international reach of patent laws
finance.yahoo.com - February 22 at 6:26 PM |
| Atyr Pharma Spikes 33% on FDA Update (LIFE)
www.investopedia.com - January 20 at 1:06 AM |
| Atyr Pharma Stock Spikes 33% on FDA Updates
www.investopedia.com - January 19 at 8:04 PM |
| aTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status - StreetInsider.com
www.streetinsider.com - January 19 at 4:52 AM |
 | Gainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC...
www.finanznachrichten.de - January 18 at 11:50 PM |
| aTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status
www.streetinsider.com - January 18 at 6:49 PM |
| FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
us.rd.yahoo.com - January 18 at 6:49 PM |
| Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares
finance.yahoo.com - December 21 at 7:06 PM |
aTyr Pharma (LIFE) Chart for Monday, May, 22, 2017
